May. 20 at 8:18 PM
$SRZN Reasons for Regeneron to buy Surrozen:
1. Eylea franchise protection and extention.
If somebody else acquirers Eylea combination drugs then that would be very weird and potentially damaging for their most important franchise.
If they buy it then they can continue selling Eylea and oneday maybe Eylea combination drugs.
2. Targeted protein degradation technology could be used to extend their Libtayo franchise which is a checkpoint inhibitor.
3. The potential of the WNT drugs to modulate the blood brain barrier could be used to make more neurology drugs against Alzheimer, stroke and multiple sclerosis.
The preclinical buyout window for a cheaper and easier acquisition is closing in the second half of 2026. After that Surrozen will get another
$100 million from the second tranche shares more milestone payments from Boehringer Ingelheim and they can raise even more money if they want.
